Cagrilintide
LongevityFor users tracking biological age and healthspan-relevant biomarkers, Cagrilintide sits within a multi-component longevity framework spanning hallmarks-of-aging from cellular (telomere, senescence, mitochondrial) through integrative (inflammaging, nutrient sensing). A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone. Cycle-based dosing over 8-12 weeks with pre-post biomarker tracking is the longevity-research convention.
Key Takeaways
Longevity lens: Cagrilintide maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers. Mechanism: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles. Longevity protocol: cycle-based 1.2-2.4 mg 1x weekly subq dosing; 8-12 week cycles favoured over continuous administration. Longevity stack partners: Epithalon, Thymalin, NAD+.
Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Slows gastric emptying, suppresses postprandial glucagon, and acts centrally in the area postrema to suppress appetite. The C16 fatty-acid sidechain enables albumin binding and once-weekly dosing. Healthspan-relevant interpretation of this mechanism asks which biomarkers move, in which direction, on what timescale. The subsections below cover the hallmark mapping, cellular and transcriptional effects, biomarker tracking, and the cycle structure favoured in longevity-research protocols for Cagrilintide.
Healthspan markers and biological age
For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after Cagrilintide cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.
Cycle-based versus continuous dosing
Cagrilintide's longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.
Cellular reprogramming and gene expression
Where Cagrilintide has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.
Cagrilintide's contribution to cellular reprogramming as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.
For epigenetic aging as a longevity-relevant endpoint, Cagrilintide is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.
Inflammaging maps to one of the hallmarks of aging and is one of the dimensions on which Cagrilintide is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.
Cagrilintide's contribution to healthspan extension as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 1.2-2.4 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1.2-2.4 mg | 4–6 weeks initial cycle |
| Longevity focus | SubQ | 1.2-2.4 mg | 1x weekly SubQ |
| Maintenance phase | SubQ | 1.2-2.4 mg | Ongoing with periodic pauses |
Dose timing for Cagrilintide is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Cagrilintide stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.
- Cagrilintide + Epithalon: Identified by Khavinson in St. Pairs naturally with Cagrilintide's mechanism in longevity / hallmarks of aging protocols.
- Cagrilintide + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with Cagrilintide's mechanism in longevity / hallmarks of aging protocols.
- Cagrilintide + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with Cagrilintide's mechanism in longevity / hallmarks of aging protocols.
- Cagrilintide + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Cagrilintide's mechanism in longevity / hallmarks of aging protocols.
Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy.
Lens-specific safety considerations for longevity / hallmarks of aging use of Cagrilintide: Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Cagrilintide | Long-acting amylin analogue | ~7 days | Longevity |
| Epithalon | Pineal-derived tetrapeptide | Very short (minutes) | A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies |
| Thymalin | Thymic polypeptide extract | Variable | A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease |
| MOTS-c | Mitochondrially-encoded peptide | Hours; tissue-distributed | A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Does Cagrilintide actually extend lifespan?
Best stack pairing for longevity?
When in life should I start Cagrilintide?
Does Cagrilintide interact with rapamycin, metformin, or other longevity stacks?
What is the standard dosing protocol for Cagrilintide?
Is Cagrilintide safe during pregnancy or breastfeeding?
Start a Cagrilintide Protocol
Alukard provides physician-supervised longevity protocols with GMP-certified Cagrilintide and GMP-certified compounds with biological age testing and healthspan markers.
Get ProtocolQuick Facts
- Molecular weight
- ~4400 Da
- Sequence length
- 37 aa
- Half-life
- ~7 days
- WADA
- Not on prohibited list
- FDA
- Investigational (Phase III combined with semaglutide as CagriSema)
- Research
- Phase III trials underway
All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Cagrilintide unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Longevity / Hallmarks of Aging Protocol for Cagrilintide
Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.
HIPAA Compliant · GMP Certified · Physician Supervised